Peter M. Voorhees, MD, discusses the 5-year follow-up results from the CARTITUDE-1 trial of ciltacabtagene autoleucel for the ...

New research suggests that certain patients with low-risk thyroid cancer can safely forgo postoperative radioiodine ablation ...

A new risk model uses objective clinical data to predict cure or relapse in Hodgkin lymphoma, with future plans to guide treatment and survivorship care.

During a live event, Jeffrey V. Matous, MD, discussed bispecific antibody treatment efficacy and safety in advanced multiple ...

A panelist highlights that after initial hemoglobin decline despite dose escalation, further increasing luspatercept dosing led to transfusion independence and hemoglobin improvement, underscoring the ...

A panelist emphasizes that recent real-world retrospective data from 103 first-line luspatercept-treated patients closely align with, and even slightly exceed, COMMANDS trial results—demonstrating ...

A panelist highlights that updated COMMANDS trial data demonstrate luspatercept’s robust efficacy in erythropoiesis-stimulating agent–naive patients with low-risk myelodysplastic syndrome—achieving ...

Panelist discusses how recent ASCO updates, particularly the SEQUOIA study results, highlight the long-term efficacy of zanubrutinib in high-risk patients and represent the most significant advances ...

An expert discusses how CT scans and bone scans remain the standard imaging approach for most patients with metastatic castration-resistant prostate cancer (mCRPC), whereas prostate-specific membrane ...

An expert discusses how the PEACE III combination of radium-223 and enzalutamide represents an effective treatment option for the limited population of patients who reach first-line metastatic ...

An expert discusses how radiopharmaceuticals such as radium-223 offer a valuable different mechanism of action in treating advanced prostate cancer, requiring careful patient selection, safety ...

Celltrion USA launches 2 denosumab biosimilars, Stoboclo and Osenvelt, enhancing treatment options for osteoporosis and ...